About 2019-07-04T12:47:43+05:30

Our Narrative

Aug 2016
Mar 2017
Nov-Dec 2017
Mar 2018
April 2018


Founded in Bangalore, India. $6Mio seed funding by Accel, Aarin, IDG, KITVEN


Development of technology platforms. Glyco-Engineering. Naïve & Synthetic Display Libraries. Development of trastuzumab biosimilar and Exendin-4.


Zumutor incorporated in USA with office in MA. Series A $6 Mio raised from existing investors. Global patents filed.

Aug 2016

Research collaboration signed with global major, Catalent, for ADCC enhancement

Mar 2017

Ideation and selection. 21 immunotherapy targets chosen.

Nov-Dec 2017

In vivo efficacy study with lead molecule initiated. Out licensed Trastuzumab biosimilar.

Mar 2018

Mouse study reveals signficant reduction in tumour growth compared to “Control IgG”.

April 2018

Raised $ 4 Mio from Accel for preclinical studies


At Zumutor , we have developed two antibody engineering platforms to facilitate our program for discovery and development of  immunotherapies that have the potential to be novel best-in-class monotherapies, and core components of innovative combination treatments.
We are committed to partnering with global biopharmaceutical companies for early stage licensing of our pipeline and to jointly discover and develop innovative products.
We have licensed our biologic product for treatment of breast cancer and are engaged in collaborations and related to our technology platforms.
For additional information on partnering with Zumutor, please contact our business development team at ramon.valencia@zumutor.com

Zumutor and Syngene Press Release

Our Team

We have committed our resources to develop treatment of cancer through next generation immunotherapies and have assembled a highly experienced team to execute our vision

Kavitha Iyer Rodrigues
Kavitha Iyer RodriguesChief Executive Officer
Kavitha is well known throughout the biotech community for her entrepreneurial acumen and leadership. She is passionate about setting new global benchmarks through Zumutor
Dr. Maloy Ghosh
Dr. Maloy GhoshChief Science Officer
Maloy heads our R &D . He is an expert in the areas of cancer biology, stem cell and biomarker development.
Dr. Sunit Maity
Dr. Sunit MaityDirector - Product Development
Sunit combines academic bandwidth with substantive industrial experience to lead our product development vertical
Anirban Bhattacharya
Anirban BhattacharyaChief Financial Officer
Experienced in licensing, mergers and acquisitions in the biopharmaceutical industry, Anirban is a consummate finance professional


Prof. Raghavan V
Prof. Raghavan VChairman, MBU Indian Institute of Science
Karthik Viswanathan
Karthik ViswanathanDirector, Research at Visterra, Inc
Cambridge, MA
Ana Anderson
Ana AndersonAss. Prof @ HMS, Member of Broad Institute of MIT, Harvard
Boston, MA
Andy Rakestraw
Andy RakestrawFounder Celexion LLC & Management Team at Torque
Cambridge, MA
Dr. Anurag Rathore
Dr. Anurag RathoreProfessor, Chemical Engineering IIT
New Delhi
Prof. Balaji Rao
Prof. Balaji RaoChemical & Biomolecular Engineering (MIT)
NCSU, Raleigh


Prof. Charles Cooney
Prof. Charles CooneyRobert T. Haslam Professor of Chemical Engineering Education
MIT, Cambridge, MA
Patrick Vink
Patrick VinkAdvisor, Global Biotechnology Industry Chairman, Targovax, NM Pharma
Zurich Area, Switzerland

Our VC Partners

We have raised a US$ 16 million in capital from Accel Partners, IDG ventures, Aarin Capital and KITVEN

Discover The Future

We attract, retain and nurture scientific talent that shares our dream of pushing the boundaries of therapeutic research. We believe in innovation and a science-based approach.

Contact Us